Fresh analysis reveals that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who end conventional diet and exercise programs.
Findings released in a leading health publication shows that while overweight people often shed a large proportion of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Users buying these drugs should be cognizant of the risk of rapid rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a reversion to original mass within about a year and a half.
Weighing Therapies
The analysis, which reviewed dozens of trials involving over 9,000 of participants, compared the effects of these new drugs with conventional dieting.
Scientists point out that individuals who lose weight through lifestyle changes alone generally have a slower weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Doctors suggest the way of the jabs accounts for the heightened regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication means hunger is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
Health authorities suggest the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts argue that, due to the likelihood of relapse, the treatment might need to be long-term.
This opinion is reinforced by drug manufacturers, who note that the findings "emphasize the chronic nature of excess weight," similar to managing conditions like hypertension.
User Experiences
Users who have discontinued the medication report a intense return of appetite.
"It felt as if a switch that goes on and I was suddenly ravenous," said a patient.
This difficulty is exacerbated if patients have not established permanent dietary or behavioural modifications during treatment.
Growing Interest
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Adoption is greater among women than males.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, researchers caution that while these medications are effective tools for weight loss, they are not a permanent solution and long-term success likely depends on combined behavioural support.
